Abstract
Status epilepticus is a state of prolonged or recurrent seizure activity that is associated with significant mortality and morbidity. At a cellular level, status epilepticus results from a failure of normal inhibitory pathways, primarily mediated by gamma-n-aminobutyric acid (GABA) acting via GABA(A) receptors. This loss of inhibitory drive allows the activation of excitatory feedback loops, leading to repetitive, synchronous firing of large groups of neurons. As seizure activity continues, there is further decline in GABAergic function. Continued excitatory input mediated primarily by glutamate leads to neuronal cell death. These alterations in inhibitory and excitatory pathways have important implications for the pharmacologic management of status epilepticus. Currently recommended agents act primarily through the GABA(A) receptor and have been shown to become less effective in status epilepticus of longer duration. Agents designed to inhibit glutamate activity show promise both in the treatment of status epilepticus and in the prevention of associated neuronal injury.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
